{"type":"trials","record":{"id":87183,"source_id":"isrctn","external_id":"ISRCTN42639823","title":"Combination photodynamic treatment and intravitreal ranibizumab versus intravitreal ranibizumab alone in neovascular age-related macular degeneration","brief_summary":"This study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration (AMD), compared to the use of intravitreal ranibizumab alone and to see whether combination treatment reduces retreatment rates.","overall_status":"Completed","phases":["Phase III"],"study_type":"Interventional","sponsor":"University Hospitals Bristol NHS Foundation Trust (UK)","enrollment":18,"countries":["United Kingdom","England"],"start_date":"2007-07-07","completion_date":"2009-01-20","last_update_date":"2012-12-04","source_url":"https://www.isrctn.com/ISRCTN42639823","editorial_summary":"A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN42639823; retrieved 2026-09-25","interventions":["Ranibizumab, verteporfin photodynamic therapy (Visudyne®)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The proportion of subjects who gain 15 or more letters of best corrected visual acuity at 12 months compared to baselin…","1. Mean change from baseline in best corrected visual acuity (BCVA) at months 6 and 12 2. Proportion of patients who ga…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Neovascular age-related macular degeneration","Intravitreal ranibizumab combined with photodynamic treatment versus intravitreal ranibizumab alone: Ranibizumab 0.5 mg…","results","Ranibizumab, verteporfin photodynamic therapy (Visudyne®)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn42639823","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2007-07-07 to 2009-01-20","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.594Z","intervention":["Ranibizumab, verteporfin photodynamic therapy (Visudyne®)","Drug"],"participants":18,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase III","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The proportion of subjects who gain 15 or more letters of best corrected visual acuity at 12 months compared to baselin…","1. Mean change from baseline in best corrected visual acuity (BCVA) at months 6 and 12 2. Proportion of patients who ga…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87183","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}